OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
OKYO Pharma (NASDAQ: OKYO) has secured $1.9 million in non-dilutive funding to accelerate the development of urcosimod, its lead drug candidate for treating Neuropathic Corneal Pain (NCP). The funding will support ongoing R&D programs and advance clinical milestones without impacting existing shareholder equity.
NCP is a severely debilitating ocular condition characterized by chronic nerve-related pain that currently has no FDA-approved treatments. The company will use the funds to advance clinical development, expand R&D efforts, and progress urcosimod's regulatory pathway, demonstrating its commitment to fiscal responsibility while developing innovative therapies.
OKYO Pharma (NASDAQ: OKYO) ha ottenuto 1,9 milioni di dollari di finanziamenti non diluitivi per accelerare lo sviluppo di urcosimod, il suo farmaco principale per il trattamento del Dolore Corneale Neuropatico (NCP). Questi fondi sosterranno i programmi di ricerca e sviluppo in corso e permetteranno di raggiungere importanti traguardi clinici senza influire sull'equity degli azionisti attuali.
Il NCP 猫 una condizione oculare gravemente debilitante, caratterizzata da un dolore cronico legato ai nervi, per la quale attualmente non esistono trattamenti approvati dalla FDA. L'azienda utilizzer脿 i fondi per far progredire lo sviluppo clinico, ampliare gli sforzi di ricerca e sviluppo e avanzare nel percorso regolatorio di urcosimod, dimostrando cos矛 il suo impegno nella responsabilit脿 finanziaria mentre sviluppa terapie innovative.
OKYO Pharma (NASDAQ: OKYO) ha asegurado 1,9 millones de d贸lares en financiamiento no dilutivo para acelerar el desarrollo de urcosimod, su principal candidato a f谩rmaco para tratar el Dolor Corneal Neurop谩tico (NCP). Los fondos apoyar谩n los programas de I+D en curso y permitir谩n avanzar en hitos cl铆nicos sin afectar el capital de los accionistas existentes.
El NCP es una condici贸n ocular gravemente discapacitante, caracterizada por dolor cr贸nico relacionado con los nervios, para la cual actualmente no existen tratamientos aprobados por la FDA. La compa帽铆a utilizar谩 los fondos para avanzar en el desarrollo cl铆nico, ampliar los esfuerzos de I+D y progresar en la v铆a regulatoria de urcosimod, demostrando su compromiso con la responsabilidad financiera mientras desarrolla terapias innovadoras.
OKYO Pharma (NASDAQ: OKYO)電� 鞁犼步氤戩劚 臧侂韱奠(NCP) 旃橂毳� 鞙勴暅 欤茧牓 鞎诫 頉勲炒鞚� 鞙犾綌鞁滊霌� 臧滊皽 臧�靻嶍檾毳� 鞙勴暣 頋劃霅橃 鞎婋姅 190毵� 雼煬鞚� 鞛愱笀鞚� 頇曤炒頄堨姷雼堧嫟. 鞚� 鞛愱笀鞚� 順勳灛 歆勴枆 欷戩澑 鞐瓣惮臧滊皽 頂勲攴鸽灗鞚� 歆�鞗愴晿瓿� 旮办〈 欤检＜ 歆�攵勳棎 鞓來枼鞚� 欤检 鞎婌溂氅挫劀 鞛勳儊 雼硠鞚� 歆勳爠鞚� 霃勲頃� 瓴冹瀰雼堧嫟.
NCP電� 毵岇劚 鞁犼步 甏�霠� 韱奠鞚� 韸轨鞚� 鞁皝頃� 鞎堦惮 歆堩櫂鞙茧, 順勳灛 FDA 鞀轨澑 旃橂鞝滉皜 鞝勲頃� 靸來儨鞛呺媹雼�. 須岇偓電� 鞚� 鞛愱笀鞚� 鞛勳儊 臧滊皽 齑夓, 鞐瓣惮臧滊皽 頇曤寑, 鞙犾綌鞁滊霌滌潣 攴滌牅 鞝堨皑 歆勴枆鞐� 靷毄頃� 鞓堨爼鞚措┌, 順侅嫚鞝侅澑 旃橂氩� 臧滊皽瓿� 頃粯 鞛爼 毂呾瀯鞚� 雼ろ晿瓴犽嫟電� 鞚橃毳� 氤挫棳欷嶋媹雼�.
OKYO Pharma (NASDAQ : OKYO) a obtenu 1,9 million de dollars de financement non dilutif afin d'acc茅l茅rer le d茅veloppement d'urcosimod, son principal candidat-m茅dicament pour le traitement de la douleur corn茅enne neuropathique (NCP). Ce financement soutiendra les programmes de R&D en cours et permettra de faire progresser les 茅tapes cliniques sans affecter les actions des actionnaires actuels.
La NCP est une affection oculaire s茅v猫rement invalidante, caract茅ris茅e par une douleur chronique li茅e aux nerfs, pour laquelle il n'existe actuellement aucun traitement approuv茅 par la FDA. L'entreprise utilisera ces fonds pour faire avancer le d茅veloppement clinique, 茅largir les efforts de R&D et progresser dans la voie r茅glementaire d'urcosimod, d茅montrant ainsi son engagement envers la responsabilit茅 financi猫re tout en d茅veloppant des th茅rapies innovantes.
OKYO Pharma (NASDAQ: OKYO) hat 1,9 Millionen US-Dollar an nicht verw盲ssernden Finanzmitteln erhalten, um die Entwicklung von Urcosimod, ihrem f眉hrenden Arzneimittelkandidaten zur Behandlung von neuropathischem Hornhautschmerz (NCP), zu beschleunigen. Die Finanzierung wird laufende F&E-Programme unterst眉tzen und klinische Meilensteine vorantreiben, ohne die bestehende Aktion盲rsbeteiligung zu verw盲ssern.
NCP ist eine schwerwiegende, beeintr盲chtigende Augenerkrankung, die durch chronische nervenbedingte Schmerzen gekennzeichnet ist und derzeit keine von der FDA zugelassenen Behandlungen hat. Das Unternehmen wird die Mittel nutzen, um die klinische Entwicklung voranzutreiben, die F&E-Bem眉hungen auszuweiten und den regulatorischen Weg von Urcosimod zu f枚rdern, wodurch es sein Engagement f眉r finanzielle Verantwortung bei der Entwicklung innovativer Therapien unterstreicht.
- Secured $1.9 million in non-dilutive funding preserving shareholder value
- Targeting an unmet medical need with no FDA-approved treatments
- Funding strengthens ability to advance clinical milestones and R&D efforts
- Current development stage suggests revenue generation still far in the future
- Funding amount relatively modest for clinical development needs
Insights
OKYO's $1.9M non-dilutive funding strengthens its financial position while advancing its lead candidate for an unmet medical need.
OKYO Pharma has secured
The funding strengthens OKYO's cash position at a critical juncture in urcosimod's development. NCP represents a substantial market opportunity as an underserved condition with no FDA-approved treatments. Patients suffering from this condition experience chronic and often severe nerve-related pain, creating a significant unmet medical need that urcosimod aims to address.
From a financial perspective, this capital infusion extends OKYO's operational runway and reduces near-term financing pressure. For clinical-stage biotechs without marketed products generating revenue, securing non-dilutive funding is exceptionally valuable. This
The company's focus on a condition lacking approved therapies positions it in a potentially advantageous regulatory environment, where treatments for unmet medical needs can sometimes benefit from accelerated review processes. This funding will help OKYO navigate the complex and costly clinical development landscape while maintaining its existing capital structure 鈥� a positive signal for current investors concerned about dilution.
LONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announced it has received
This non-dilutive capital strengthens OKYO Pharma鈥檚 ability to execute on its development strategy without impacting existing shareholder equity. The funds will be used to advance key clinical milestones, expand R&D efforts, and build momentum behind urcosimod鈥檚 regulatory pathway.
鈥淭his non-dilutive funding is a significant milestone for OKYO Pharma and allows the company to drive innovation and accelerate solutions that could improve patient outcomes,鈥� said Gary S. Jacob, PhD, CEO of OKYO Pharma. 鈥淣europathic Corneal Pain is a devastating and underdiagnosed condition with no approved therapies. These funds allow us to aggressively pursue our mission of bringing urcosimod to patients who desperately need relief, without diluting shareholder value. It鈥檚 an exciting step forward for our company and for the field of ocular pain treatment.鈥�
The infusion of non-dilutive funding underscores OKYO Pharma鈥檚 commitment to maintaining fiscal responsibility while pursuing transformative therapies that address critical unmet medical needs.
About NCP
聽is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause of neuropathic corneal pain is unknown but is thought to result from nerve damage to the聽聽combined with聽. Neuropathic corneal pain, which can exhibit as a severe, chronic, debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated by various topical and systemic treatments in an off-label fashion. Notably, there is no FDA approved drug to treat this debilitating condition.
About Urcosimod (Formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating ocular diseases. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the efficacy of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and just completed a randomized, placebo-controlled, double-masked Phase 2 trial of urcosimod to treat neuropathic corneal pain.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. A Phase 2 trial of urcosimod to treat neuropathic corneal pain patients was just completed by OKYO.
For further information, please visit聽.
Inquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
How much non-dilutive funding did OKYO Pharma (NASDAQ: OKYO) receive in July 2025?
What is OKYO Pharma developing urcosimod for?
How will OKYO use the $1.9 million funding?
What is the current treatment landscape for Neuropathic Corneal Pain?
How does the funding impact OKYO Pharma shareholders?
